Amedisys (AMED)
(Delayed Data from NSDQ)
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Envision Healthcare Divests AMR Unit, Streamlines Business
by Zacks Equity Research
Envision Healthcare (EVHC) divests its American Medical Response business to reduce leverage and focus on high-growth business.
5 Growth Stocks in MedTech Set to Scale Higher in 2018
by Zacks Equity Research
The U.S. MedTech markets have been riding high with merger and acquisitions in focus.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) witnesses encouraging growth in Medicare and non-Medicare revenues at the Home Health and Hospice divisions in fourth-quarter 2017.
Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit
by Zacks Equity Research
Amedisys (AMED) forges ahead with buyouts to boost capacity and geographical presence.
Amedisys (AMED) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Amedisys (AMED) registers strong growth across all segments in Q4.
Amedisys (AMED) Strong on Home Health, Margin Decline a Woe
by Zacks Equity Research
Amedisys' (AMED) acquisition of Tenet Healthcare's home health and hospice operations in Arizona might help the company deliver high-quality post-acute services in the key markets.
Veeva Systems' Product Portfolio Strong, Competition Rife
by Zacks Equity Research
Veeva Systems (VEEV) rides on growing demand for cloud-based and vault applications. However, the company faces cutthroat competition in the niche space.
Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abaxis (ABAX) rides high on recently received approval from USDA.
Intuitive Surgical Gains on FDA Approvals, Competition Rife
by Zacks Equity Research
Intuitive Surgical (ISRG) gains significantly on CE Mark approval for da Vinci X in Europe.
Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical (ISRG) gains from revenue growth in Instrument & Accessories plus Services and Systems segments in Q4.
PerkinElmer (PKI) Beats on Q4 Earnings, Issues 2018 Guidance
by Zacks Equity Research
Solid performance in Discovery & Analytical Solutions segment drives PerkinElmer (PKI) in Q4. A strong guidance for FY18 instills investor's optimism.
Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance
by Zacks Equity Research
Abbott (ABT) posts promising Q4 results on strong growth in all lines and expansion in emerging markets.
Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q2.
AngioDynamics (ANGO) Banks on Buyouts, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.
Walgreens Boots' Retail Pharmacy Strong, Competition Rife
by Zacks Equity Research
Walgreens Boots (WBA) rides high on continued prescription growth and strength in the Retail Pharmacy USA division.
PetMed (PETS) Q3 Earnings Top Estimates, Reorder Sales Solid
by Zacks Equity Research
The upside in third-quarter fiscal 2018 sales at PetMed (PETS) is a result of the significant increase in new orders and reorder sales.
ResMed (RMD) Beats Q2 Earnings & Sales on Growth in All Lines
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q2 on solid contributions from domestic and international businesses.
Medtronic's FDA Nod for Riptide Aspiration System Boosts RTG
by Zacks Equity Research
Medtronic (MDT) makes efforts to boost RTG business.
Medtronic (MDT) Wins FDA Nod for New Clinician Programmer
by Zacks Equity Research
Medtronic's (MDT) latest FDA nod likely to boost Pain Therapies division.
5 Reasons Why You Should Offload Wright Medical Stock Now
by Zacks Equity Research
Foreign currency fluctuations and pricing pressure continue to be major headwinds for Wright Medical Group (WMGI).
Medtronic's ITB Therapy Superior to CMM for PSS Reduction
by Zacks Equity Research
Medtronic (MDT) consistently tries efforts to boost Pain Therapies division, part of the Restorative Therapies Group.
Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.
QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.
Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq
by Zacks Equity Research
Illumina (ILMN) consistently tries to enhance NGS platform.
Express Scripts 90-Day Analysis of Opioid Management Positive
by Zacks Equity Research
Express Scripts (ESRX) addresses the national opioid epidemic by reducing excessive and improper opioid use.